Venetoclax in Higher-Risk MDS/AML

CPX-351 plus venetoclax in patients with newly-diagnosed high-risk AMLПодробнее

Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and managementПодробнее

What’s on the horizon for higher-risk MDS? An update on emerging novel agents?Подробнее

MDS - Myeloplastic Syndromes - 2023 Best of Hematology ConferenceПодробнее

Azacitidine and Venetoclax for High-risk #MDS Patients | Jacqueline S. Garcia, MD | ASH 2023Подробнее

Sorafenib or venetoclax in fractionated busulfan conditioning regimen for AML & MDSПодробнее

How could venetoclax combinations improve outcome in high-risk MDS?Подробнее

Community Perspectives on Acute Myeloid Leukemia and Higher-Risk Myelodysplastic SyndromeПодробнее

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?Подробнее

Phase I study of ven/aza maintenance therapy following ven/FluBu2 RIC alloSCT in high-risk MDS/AMLПодробнее

ASTX727 plus venetoclax: Phase I study of total oral therapy for high-risk MDS/CMMLПодробнее

Q&A with Katharina GötzeПодробнее

Venetoclax and magrolimab for treatment of AML and MDSПодробнее

Dose modification strategies in high-risk MDS treated with venetoclax and azacitidineПодробнее

Venetoclax plus azacitidine in treatment-naïve higher-risk MDSПодробнее

What's New in MDS May 19 2021Подробнее

Optimizing Care for High-Risk Myeloid Cancers: Interprofessional Team InsightsПодробнее

SESSION III HIGH RISK MDS - (English) - Latin-American GLAM and MDSF Symposium 2021Подробнее

CAR T Cell Therapy in MDS/AMLПодробнее

Advancing the treatment of MDS and AML: An update from ASH 2021Подробнее